|
Jordan Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Jordan Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Jordan.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Jordanian pharmaceutical and healthcare industry.
Competitive intelligence, Jordanian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Jordanian market.
The Jordan Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Jordan Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Jordanian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Jordan to test other views – a key input for successful budgeting and strategic business planning in the Jordanian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Jordanian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Jordan.
- Exploit The Latest Competitive Jordanian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Jordan.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Jordan Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Jordan Pharmaceuticals And Healthcare Industry SWOT |
| Jordan Political SWOT |
| Jordan Economic SWOT |
| Jordan Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Regional Pharma Business Environment Ratings Q209 |
| Limits To Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Market Summary |
| Regulatory Regime |
| Intellectual Property Developments |
| Counterfeit Pharmaceuticals |
| Pricing And Reimbursement Issues |
| International Collaboration |
Chapter - Industry Developments |
| Epidemiology |
| Healthcare Sector |
| Recent Healthcare Sector Developments |
| Medical Tourism |
| Domestic Pharmaceuticals Sector |
| Recent Domestic Company Activities |
| Foreign Companies |
| Retail Pharmacy Sector |
| Research And Development Sector |
| Clinical Trials |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecasts |
| Table: Jordan – Drug Market Expenditure Indicators, 2004-2013 (JODmn unless otherwise indicated) |
| Key Growth Factors – Industry |
| Table: Jordan – Healthcare Expenditure Indicators, 2004-2013 (JODmn unless otherwise indicated) |
| Macroeconomic Forecast |
| Table: Jordan – Macroeconomic Forecast |
| Prescription Drug Market Forecast |
| Table: Jordan – Prescription Market Indicators, 2004-2013 (US$mn unless otherwise stated) |
| OTC Drug Market Forecast |
| Table: Jordan – OTC Market Indicators, 2004-2013 (US$mn unless otherwise stated) |
| Patented Drug Market Forecast |
| Table: Jordan – Patented Drugs Market Indicators, 2004-2013 (JODn unless otherwise indicated) |
| Generic Drug Market Forecast |
| Table: Jordan – Generics Market Indicators, 2004-2013 (JODn unless otherwise indicated) |
| Medical Device Market Forecast |
| Table: Jordan Medical Device Market 2004-2013 |
| Import/Export Forecasts |
| Table: Jordan – Pharmaceutical Trade Indicators, 2004-2013 (US$mn) |
| Other Healthcare Data Forecasts |
| Table: Other Healthcare Indicators, 2004-2013 |
| Key Risks To BMI's Forecasts |
Chapter - Competitive Landscape |
| Table: Top Six Drugmakers In Jordan, H107 |
Chapter - Company Profiles |
| Multinational Companies |
| Novartis |
| Sanofi-Aventis |
| Pfizer |
| GlaxoSmithKline |
| Merck & Co |
| Indigenous Manufacturers |
Chapter - Pharma International Company |
| Arab Pharmaceutical Manufacturers (APM) |
| Dar Al Dawa (DAD) |
| Hikma Pharmaceuticals |
| Jordanian Pharmaceutical Manufacturing (JPM) |
| United Pharmaceutical Manufacturers |
| Arab Pharmaceutical Manufacturers (APM) |
| Dar Al Dawa (DAD) |
| Hikma Pharmaceuticals |
| Jordanian Pharmaceutical Manufacturing (JPM) |
Chapter - Country Snapshot: Jordan Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Consumer Expenditure, 2000-2012 |
| Table: Average Annual Manufacturing Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Jordan Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
BMI has revised its extended forecast for Jordan’s pharmaceutical and healthcare market for our Q209 report. We expect the total drug market to grow from US$370mn in 2008 to US$540mn by 2013, representing a compound annual growth rate (CAGR) of 7.87%. The main drivers for growth include the continuing high volume medicine export activity, generated by Jordan’s domestic drug manufacturers. Additionally, the epidemiological profile of Jordan indicates an increasing burden of obesity and diabetes- related disorders, which will drive spending in overall healthcare.
The Ministry of Health in Jordan announced that healthcare services are facing rising pressure as rapid population growth increases demands. The efficiency and allocation of available public medical resources needs to be revised to account for the influx of refugees, in addition to the year-on-year (y-o-y) 2.8% population growth rate. BMI notes that, while government healthcare spending must adjust to match demand, consistent public health insurance policies will result in more efficient spending in this sector.
Overall health expenditure in Jordan rose by 7.9% during 2008, which we expect to continue through to 2009. We believe that increasing resources for medical services by providing more hospitals and doctors will address the main issues outlined by the Ministry of Health. Previous temporary measures to alleviate public sector shortages involved medically insured government employees paying 20% toward the cost of fees at participating private hospitals, with the remainder paid by the state.
The Private Hospital Association (PHA) ended the scheme and further negotiations with the government later in 2008. BMI believes this is a major setback for Jordan, however it will further underline the inefficiencies of the public health sector and will encourage the government to re-evaluate its strategies for financing and providing medical services.
While the state plans to restructure the Jordanian healthcare system, we note that existing health facilities are under-utilised, mainly due to the lack of interaction between the three main health providers.
Increasing the capital allocated for healthcare will be achieved through the government's target to 100% public or private medical insurance coverage by 2012. Currently, the government estimates that 86% of people are covered by either type of health insurance, and therefore we believe its target is achievable.|
Jordan Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |